<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1406233806
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1990
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FAVERIN 50MG EC TABS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FLUVOXAMINE MALEATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        82.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Mylan Laboratories SAS " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Mylan Laboratories SAS 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ABBOTT HEALTHCARE PRODUCTS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Faverin belongs to a group of medicines called selective serotonin re-uptake inhibitors (SSRI). Faverin contains a substance called fluvoxamine. This is an antidepressant. It is used to treat depression (major depressive episode).</p><p>&nbsp;</p><p>Faverin can also treat people who have obsessive thoughts and/or compulsive behaviour (obsessive compulsive disorder, OCD).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take this medicine if:</strong></p><p>- &nbsp; you are allergic (hypersensitive) to fluvoxamine or any of the other ingredients (listed in section 6).</p><p>- &nbsp; You are taking pimozide, a neuroleptic drug that is used for the treatment of schizophrenia and other psychiatric diseases.</p><p>- &nbsp; you are taking medicines called monoamine oxidase inhibitors (MAOI) sometimes prescribed to treat depression or anxiety, including linezolid (an antibiotic which is also a MAOI). Treatment with fluvoxamine should only be started at least 2 weeks after discontinuation of an irreversible MAOI. However treatment with fluvoxamine after discontinuation of certain reversible MAOIs can be started the following day. In exceptional cases linezolid (an antibiotic MAOI) may be used with fluvoxamine provided the doctor can monitor you closely. Your doctor will advise you how you should begin taking Faverin once you have stopped taking the MAOI.</p><p>- &nbsp; you are taking tizanidine, a medicine often used as a muscle relaxant.</p><p>- &nbsp; you are breast-feeding.</p><p>&nbsp;</p><p>If any of the above apply to you, do not take Faverin and talk to your doctor.</p><p>&nbsp;</p><p><strong>Take special care</strong></p><p>Talk to your doctor or a pharmacist before taking this medicine if:</p><p>- &nbsp; you recently had a heart attack</p><p>- &nbsp; you are pregnant, or could be pregnant</p><p>- &nbsp; you have epilepsy</p><p>- &nbsp; you have a history of bleeding problems or if you regularly use medicines which increase the risk of bleeding, such as common pain killers, or if you are pregnant (see &lsquo;Pregnancy&rsquo;)</p><p>- &nbsp; you have diabetes</p><p>- &nbsp; you are having treatment with electroconvulsive therapy (ECT)</p><p>- &nbsp; you ever had mania (a feeling of elation or over-excitement)</p><p>- &nbsp; you have liver or kidney problems</p><p>- &nbsp; you have high pressure in your eyes (glaucoma)</p><p>- &nbsp; you are less than 18 years old (see also section 3 &ldquo;How to take Faverin&rdquo;)</p><p>&nbsp;</p><p>If any of the above applies to you, your doctor will tell you whether it is safe for you to start taking Faverin.</p><p>&nbsp;</p><p>Occasionally, thoughts of restlessness (for example, you cannot sit or stand still (akathisia) may occur or may increase during the first few weeks of treatment with Faverin, until the antidepressant effect has worked.</p><p>Tell your doctor immediately if you experience these symptoms. Then a dosage adjustment may be helpful.</p><p>&nbsp;</p><p>Severe skin reactions have been reported when using Fevarin. <strong>Stop taking </strong>Fevarin and contact a doctor immediately if you develop a rash or mucous membrane lesions. The severe rashes may include rash, starting on the extremities, usually on both sides of the body and evolving into concentric circles that resemble a target (erythema multiforme), widespread rash with blisters and peeling skin, particularly occurring around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome), extensive peeling of the skin (more than 30% of the body surface &ndash; toxic epidermal necrolysis).</p><p>Medicines like Fevarin (so called SSRIs) may cause symptoms of sexual dysfunction (see section 4). In some cases, these symptoms have continued after stopping treatment.</p><p>&nbsp;</p><p><strong>Thoughts of suicide and worsening of your depression or anxiety disorder</strong></p><p>If you are depressed and/or have anxiety disorders, you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.</p><p>You may be more likely to think like this:</p><p>- &nbsp; If you have previously had thoughts about killing or harming yourself.</p><p>- &nbsp; If you are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviour in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant.</p><p>If you have thoughts of harming or killing yourself at any time, <strong>contact your doctor or go to a hospital straight away.</strong></p><p>&nbsp;</p><p><strong>You may find it helpful to tell a relative or close friend</strong> that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour.</p><p>&nbsp;</p><p><strong>Tell your doctor immediately</strong> if you have any distressing thoughts or experiences.</p><p>&nbsp;</p><p><strong>Use in children and adolescents under 18 years of age</strong></p><p>Children and adolescents under 18 years should not take this medicine, unless they are being treated for OCD (obsessive compulsive disorder, obsessive thoughts and/or compulsive behaviour).</p><p>This is because Faverin is not used to treat depression in people aged under 18 years.</p><p>&nbsp;</p><p>When taking this type of medicine, people under 18 have an increased risk of side effects such as attempting suicide, thoughts about suicide and hostility, such as aggression, oppositional behaviour and anger.</p><p>&nbsp;</p><p>If your doctor has prescribed Faverin for someone under 18 years and you want to discuss this, please go back to your doctor. You should tell your doctor if any of the symptoms listed above develop or worsen when patients under 18 are taking Faverin.</p><p>&nbsp;</p><p>Also, it is not known whether taking Faverin under the age of 18 years can affect growth, maturation or development of intelligence or behaviour in the long term.</p><p>&nbsp;</p><p><strong>Other medicines and Faverin</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>- &nbsp; You should not start to take the herbal remedy St John&#39;s Wort while you are being treated with Faverin since this may result in an increase of undesirable effects. If you are already taking St John&#39;s Wort when you start on Faverin, stop taking the St John&rsquo;s Wort and tell your doctor at your next visit.</p><p>- &nbsp; If you have been taking a medicine to treat depression or anxiety within the last two weeks, or you suffer from schizophrenia, check with your doctor or a pharmacist.</p><p>&nbsp;</p><p>Your doctor or pharmacist will check if you are taking other medicines to treat your depression or other related psychotic conditions, these may include:</p><p>- &nbsp; benzodiazepines</p><p>- &nbsp; tricyclic antidepressants</p><p>- &nbsp; neuroleptic or anti-psychotics</p><p>- &nbsp; lithium</p><p>- &nbsp; tryptophan</p><p>- &nbsp; monoamine oxidase inhibitors (MAOI) such as moclobemide</p><p>-&nbsp;&nbsp; Pimozide</p><p>- &nbsp; selective serotonin reuptake inhibitors (SSRI) such as citalopram</p><p>&nbsp;</p><p>Your doctor will tell you if it is safe for you to start taking Faverin.</p><p>&nbsp;</p><p>You should also tell your doctor or pharmacist if you have <strong>been taking any of the medicines listed below:</strong></p><p>-&nbsp;&nbsp; aspirin (acetylsalicylic acid) or aspirin-like medicines, used to treat pain and inflammation (arthritis)</p><p>-&nbsp;&nbsp; ciclosporin, used to reduce the activity of the immune system</p><p>- &nbsp; methadone, used to treat pain and withdrawal symptoms</p><p>- &nbsp; mexiletine, used to treat abnormal heart rhythms</p><p>- &nbsp; phenytoin or carbamazepine, used to treat epilepsy</p><p>- &nbsp; propranolol, used to treat high blood pressure and heart conditions</p><p>- &nbsp; ropinirole, for Parkinson&#39;s disease</p><p>- &nbsp; a &ldquo;triptan&rdquo;, used to treat migraines, such as sumatriptan</p><p>- &nbsp; terfenadine, used to treat allergies. Faverin should not be taken together with terfenadine</p><p>- &nbsp; sildenafil, used to treat erectile dysfunction</p><p>- &nbsp; theophylline, used to treat asthma and bronchitis</p><p>- &nbsp; tramadol, a pain-killer</p><p>- &nbsp; clopidogrel, warfarin, nicoumalone or any other drug used to prevent blood clots</p><p>&nbsp;</p><p>If you are taking or have recently taken any of the medicines in the above list and you have not already discussed these with your doctor, go back to your doctor and ask what you should do. Your dose may need to be changed or you may need to be given a different medicine.</p><p>&nbsp;</p><p>Please tell your doctor or pharmacist if you are taking or have taken Faverin with any other medicines. Including medicines obtained without a prescription. This includes herbal medicines.</p><p>&nbsp;</p><p><strong>Taking Faverin with food and drink</strong></p><p>Do not drink alcohol if you are taking Faverin. This is because alcohol works together with Faverin and will make you sleepy and unsteady.</p><p>&nbsp;</p><p>If you normally drink a lot of tea, coffee and soft drinks with caffeine in them, you may have symptoms such as your hands shaking, feeling sick, fast heart rate (palpitations), restlessness and difficulty sleeping (insomnia). If you lower how much caffeine you drink, these symptoms might disappear.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>There is only limited experience concerning the use of fluvoxamine during pregnancy. <strong><u>Do not take fluvoxamine if you are pregnant unless your doctor considers it absolutely necessary. If you are currently taking fluvoxamine and are planning to become pregnant or to father a child, please consult with your physician to decide if an alternative medication is necessary or appropriate. </u></strong></p><p><strong><u>&nbsp;</u></strong></p><p>If you take fluvoxamine near the end of your pregnancy there may be an increased risk of heavy</p><p>vaginal bleeding shortly after birth, especially if you have a history of bleeding disorders. Your</p><p>doctor or midwife should be aware that you are taking fluvoxamine so they can advise you.</p><p>&nbsp;</p><p>Fluvoxamine has been shown to reduce the quality of sperm in animal studies. Theoretically, this could affect fertility, but impact on human fertility has not been observed yet.</p><p>&nbsp;</p><p>Make sure your midwife and/or doctor know you are on fluvoxamine. When taken during pregnancy, particularly in the last 3 months of pregnancy, medicines like fluvoxamine may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby you should contact your midwife and/or doctor immediately.</p><p>&nbsp;</p><p>You should not discontinue treatment with fluvoxamine abruptly. Tell your doctor if you are taking fluvoxamine during the last 3 months of pregnancy, your baby might have some other symptoms when it is born in addition to having trouble breathing or bluish skin, such as not being able to sleep or feed properly, being too hot or cold, being sick, crying a lot, stiff or floppy muscles, lethargy, drowsiness, tremors, jitters or fits. If your baby has any of these symptoms when it is born contact your doctor immediately.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Fluvoxamine passes into breast milk. There is a risk of an effect on the baby. Therefore, you should discuss the matter with your doctor. He/she will decide whether you should stop breast-feeding or stop the therapy with fluvoxamine. There are no data on the effect of fluvoxamine on milk production</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>You can drive and use machines while you are taking Faverin, so long as this medicine does not make you sleepy.</p><p>&nbsp;</p><p><strong>Faverin contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially `sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much Faverin to take</strong></p><p>Always take this medicine exactly as your doctor has told you to. You should check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Usual starting dose for adults (18 years and older):</strong></p><p><strong>&nbsp;</strong></p><p><u>Treatment for depression:</u></p><p>- &nbsp; Start with 50 or 100 mg daily, taken in the evening.</p><p>&nbsp;</p><p><u>Treatment for obsessive compulsive disorder:</u></p><p>- &nbsp; Start with 50 mg daily, preferably in the evening.</p><p>&nbsp;</p><p>If you don&rsquo;t start to feel better after a few weeks, talk to your doctor, who will advise you. He or she may decide to increase the dose gradually.</p><p>&nbsp;</p><p>The highest daily dose that is recommended is 300 mg.</p><p>&nbsp;</p><p>If your doctor advises you to take more than 150 mg per day, <strong>do not take them all at once;</strong> ask your doctor when you should take them.</p><p>&nbsp;</p><p><strong>The usual dose for children and adolescents with obsessive compulsive disorder &ndash; OCD (8 years and older):</strong></p><p>Start with 25 mg (half a tablet) per day, preferably at bedtime. Your doctor may increase the dose every 4-7 days in 25 mg increments as tolerated until an effective dose is achieved.</p><p>The highest daily dose is 200 mg.</p><p>&nbsp;</p><p>If your doctor advises you to take more than 50 mg per day, <strong>do not take them all at once;</strong> ask your doctor when you should take them. If the dose is not divided equally, the larger dose should be taken at night.</p><p>&nbsp;</p><p>Children and adolescents under the age of 18 should not take this medicine to treat depression. This medicine should be prescribed for children or adolescents for Obsessive Compulsive Disorder (OCD) only.</p><p>&nbsp;</p><p><strong>How to take Faverin</strong></p><p>Swallow the tablets with water. Do not chew them.</p><p>You can break the tablets in half if your doctor has advised you to do this.</p><p>&nbsp;</p><p><strong>How long does it take to work</strong></p><p>Faverin may take a little time to start working. Some patients do not feel better in the first 2 or 3 weeks of treatment.</p><p>&nbsp;</p><p>Keep taking your tablets until your doctor tells you to stop. Even when you start feeling better, your doctor may want you to carry on taking Faverin for some time, for at least 6 months to make sure that the medication has worked completely.</p><p><strong>Do not stop</strong> taking Faverin too quickly. You may suffer from <strong>withdrawal symptoms</strong> such as:</p><p>- agitation and anxiety,</p><p>- confusion,</p><p>- diarrhoea,</p><p>- difficulty sleeping/ intense dreams</p><p>- dizziness,</p><p>- emotional instability,</p><p>- headaches,</p><p>- irritability,</p><p>- nausea and/or vomiting,</p><p>- palpitations (faster heartbeat),</p><p>- sensory disturbance (such as electric shock sensations or visual disturbances),</p><p>- sweating,</p><p>- tremors.</p><p>&nbsp;</p><p>When stopping Faverin, your doctor will help you to reduce your dose slowly over a number of weeks or months. This should help reduce the chance of withdrawal effects. Most people find that any symptoms on stopping Faverin are mild and go away on their own within two weeks. For some people, these symptoms may be more severe, or go on for longer.</p><p>&nbsp;</p><p>If you get withdrawal effects when you are coming off Faverin your doctor may decide that you should come off them more slowly. If you get severe withdrawal effects when you stop taking Faverin, please see your doctor. He or she may ask you to start taking your tablets again and come off them more slowly (see section 4 &ldquo;Possible side effects&rdquo;).</p><p>&nbsp;</p><p>If you experience any symptoms on stopping the treatment, contact your doctor.</p><p>&nbsp;</p><p><strong>If you take more Faverin than you should</strong></p><p>If you or someone else takes too much Faverin (an overdose), talk to a doctor or go to a hospital straight away. Take the medicine pack with you.</p><p>&nbsp;</p><p>Symptoms of overdose include, but not limited to, nausea, vomiting, diarrhoea and feeling drowsy or dizzy. Cardiac events (slow or fast heartbeat, low blood pressure), liver problems, convulsions (fits) and coma have also been reported.</p><p>&nbsp;</p><p><strong>If you forget to take Faverin</strong></p><p>If you miss a tablet, wait until the next dose is due. Do not try to make up for the dose you have missed.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines Faverin can cause side effects, but not everyone gets them.<br />Frequencies of the observed side effects are defined as:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>very common</td><td>(affects more than 1 user in 10)</td></tr><tr><td>common</td><td>(affects 1 to 10 users in 100)</td></tr><tr><td>uncommon</td><td>(affects 1 to 10 users in 1,000)</td></tr><tr><td>rare</td><td>(affects 1 to 10 users in 10,000)</td></tr><tr><td>very rare</td><td>(affects less than 1 user in 10,000)</td></tr><tr><td>not known</td><td>(frequency cannot be estimated from the available data)</td></tr></tbody></table><p><strong>Side effects related to this type of medicine</strong></p><p><strong>&nbsp;</strong></p><p>Occasionally, <strong>thoughts of suicide or self harm</strong> may occur or may increase in the first few weeks of treatment with Faverin, until the antidepressant effect has worked.</p><p><strong>Tell your doctor immediately</strong> if you have any distressing thoughts or experiences.</p><p>&nbsp;</p><p>If you <strong>have several symptoms at the same time</strong> you might have one of the following rare conditions:</p><p>- &nbsp; Serotonin syndrome: if you have sweating, muscle stiffness or spasms, instability, confusion, irritability or extreme agitation.</p><p>- &nbsp; Neuroleptic malignant syndrome: if you have stiff muscles, high temperature, confusion and other related symptoms.</p><p>SIADH: if you feel tired, weak or confused and have achy, stiff or uncontrolled muscles.</p><p>Severe skin reactions like severe skin rashes or redness, including rash, starting on the extremities, usually on both sides of the body and evolving into concentric circles that resemble a target (erythema multiforme)<em>, </em>widespread rash with blisters and peeling skin,</p><p>particularly occurring around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome), extensive peeling of the skin (more than 30% of the body surface &ndash; toxic</p><p>epidermal necrolysis). The frequency of these side effects is not known (cannot be estimated from the available data).</p><p><strong>Stop</strong> taking Faverin and <strong>contact your doctor immediately</strong>.</p><p>&nbsp;</p><p>If unusual bruising or purple patches appear on your skin or you vomit blood or pass blood in your stool, contact your doctor for advice.</p><p>&nbsp;</p><p>Stopping of fluvoxamine (particularly when abrupt) commonly leads to withdrawal symptoms (see &ldquo;Withdrawal symptoms&rdquo; in section 3).</p><p>&nbsp;</p><p>Sometimes patients feel <strong>slightly sick</strong> as Faverin begins to work. Although the feeling of sickness is unpleasant, it should soon pass if you keep taking your tablets as prescribed. This may take a few weeks.</p><p>&nbsp;</p><p><strong>Side effects specifically related to Faverin</strong></p><p><strong>&nbsp;</strong></p><p><u>Common side effects:</u></p><p>- &nbsp; agitation</p><p>- &nbsp; anxiety</p><p>- &nbsp; constipation</p><p>- &nbsp; diarrhoea</p><p>- &nbsp; difficulty sleeping</p><p>- &nbsp; dizziness</p><p>- &nbsp; dry mouth</p><p>- &nbsp; faster heart beat</p><p>- &nbsp; feeling drowsy (lethargy)</p><p>- &nbsp; feeling unwell (malaise)</p><p>- &nbsp; headache</p><p>- &nbsp; indigestion</p><p>- &nbsp; loss of appetite</p><p>- &nbsp; nervousness</p><p>- &nbsp; stomach pain</p><p>- &nbsp; sweating</p><p>- &nbsp; tremor</p><p>- &nbsp; muscle weakness (asthenia)</p><p>- &nbsp; vomiting</p><p>&nbsp;</p><p><u>Uncommon side effects:</u></p><p>-&nbsp;&nbsp; allergic skin reactions (including swelling of face, lip or tongue, rash or itching)</p><p>- &nbsp; confusion</p><p>- &nbsp; delayed ejaculation</p><p>- &nbsp; dizziness when standing up too quickly</p><p>- &nbsp; hallucinations</p><p>- &nbsp; lack of coordination</p><p>- &nbsp; muscle or joint pain</p><p>- aggression</p><p><u>Rare side effects:</u></p><p>- &nbsp; convulsions</p><p>- &nbsp; liver complaints</p><p>- &nbsp; mania feeling of elation or over-excitement</p><p>- &nbsp; sensitivity to sunlight</p><p>- &nbsp; unexpected milk flow</p><p>&nbsp;</p><p><u>Other side effects reported:</u></p><p>- &nbsp; akathisia (restlessness)</p><p>- &nbsp; abnormal taste</p><p>- &nbsp; anorgasmy (failure to achieve orgasm)</p><p>- &nbsp; for female patients: disorders with menstruation (monthly bleeding)</p><p>- &nbsp;&nbsp;heavy vaginal bleeding shortly after birth (postpartum haemorrhage), see Pregnancy in section 2 for more information</p><p>-&nbsp;&nbsp; micturition disorders (such as the need to urinate frequently during the day and/or the night, the sudden lack of control over urination during the day and/or the night, or the lack of ability to urinate)</p><p>-&nbsp;&nbsp; paraesthesia (tingling or numbness)</p><p>-&nbsp;&nbsp; glaucoma (increased pressure in eye)</p><p>-&nbsp;&nbsp; dilated pupils</p><p>-&nbsp;&nbsp; increase in the hormone prolactin (a hormone that supports milk production in a nursing mother)</p><p>-&nbsp;&nbsp; weight changes</p><p>&nbsp;</p><p>An increased risk of bone fractures has been observed in patients taking this type of medicine.</p><p>&nbsp;</p><p><u>Side effects related to the treatment for OCD, in children and adolescents (no frequencies are given):</u></p><p>- &nbsp; hypomania (feeling of elation and over excitement)</p><p>- &nbsp; agitation</p><p>- &nbsp; convulsions</p><p>- &nbsp; difficulty sleeping (insomnia)</p><p>- &nbsp; lack of energy (asthenia)</p><p>- &nbsp; hyperactivity &nbsp;(hyperkinesia)</p><p>- &nbsp; feeling drowsy (somnolence)</p><p>- &nbsp; indigestion</p><p>&nbsp;</p><p>If any of the side effects become serious, or if you notice any side effects that are not listed in this leaflet, please tell your doctor or pharmacist. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>To report any side effect(s):</strong></p><p>-National Pharmacovigilance Center (NPC)</p><p><strong>o </strong>Fax: +966-11-205-7662</p><p><strong>o </strong>SFDA Call Center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- &nbsp; Keep out of the reach and sight of children.</p><p>- &nbsp; Do not store above 25&deg;C.</p><p>-&nbsp;&nbsp; Shelf life: 3 years</p><p>&nbsp;</p><p>Do not use Faverin after the expiry date which is printed on the carton and blister pack after EXP.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Faverin contains<br />The active substance is fluvoxamine maleate. Each tablet contains 50 mg or 100 mg of fluvoxamine<br />maleate.<br />The other ingredients are: mannitol (E421), maize starch, pregelatinized starch, sodium colloidal<br />anhydrous silica, hypromellose, macrogol 6000, talc and titanium dioxide (E171).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Faverin looks like and contents of the pack
Faverin 50 mg tablets: film-coated, white to off-white, round and marked “291” on both sides of the
score line.
Faverin 100 mg tablets: film-coated, white to off-white, oval and marked “313” on both sides of the
score line.
Faverin 50 mg is available in packs of 5, 10, 20, 30, 50, 60, 90, 100 and 250 tablets.
Faverin 100 mg is available in packs of 15, 20, 30, 50, 60, 90, 100, 120 or 250 tablets.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder<br />Abbot Healthcare Products B.V.,<br />Netherlands<br />Manufacturer<br />Mylan Laboratories SAS<br />01400 Ch&acirc;tillon-sur-Chalaronne, France<br />Packager<br />AJA Pharmaceutical Industries Company Ltd. (AJA Pharma)<br />Hail 55414 , Hail Industry City MODON<br />Kingdom of Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تنتمي أقراص فافيرين إلى مجموعة من الأدوية تسمى مثبطات إعادة امتصاص السيروتونين الانتقائية (SSRI) . حيث يحتوي فافيرين على مادة تسمى فلوفوكسامين والتي تعمل كمضادة للاكتئاب . يتم استخدامه لعلاج الاكتئاب (نوبات الاكتئاب الكبرى).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن &nbsp;استخدام فافيرين &nbsp;أيضا &nbsp;في علاج الأشخاص الذين &nbsp;يعانون من الأفكار الوسواسية و / أو السلوك القهري (اضطراب الوسواس القهري ، OCD) .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;لا &nbsp;تستخدم أقراص فافيرين إذا كنت:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من فرط الحساسية (حساسية) لفلوفوكسامين أو أي من المكونات الأخرى لأقراص فافيرين (المدرجة في القسم 6) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول بيموزيد، وهو دواء مضاد للذهان يستخدم لعلاج مرض انفصام الشخصية وأمراض نفسية أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدوية تسمى مثبطات أنزيم أكسيداز أحادي الأمين &nbsp;(MAOI) والتي توصف أحيانا لعلاج الاكتئاب أو القلق ، بما في ذلك لينزوليد (مضاد حيوي وهو أيضا من مجموعة MAOI). وينبغي أن تبدأ العلاج بتناول فلوفوكسامين على الأقل بعد أسبوعين من التوقف عن تناول الأدوية الأخرى من مجموعةMAOI &nbsp;الغير قابلة للعكس. ومع ذلك يمكن بدء العلاج بفلوفوكسامين في اليوم التالي بعد التوقف عن العلاج ببعض MOAI القابلة للعكس. وفي حالات استثنائية يمكن استخدام لينزوليد (مضاد حيوي من مجموعة MAOI) مع فلوفوكسامين شريطة أن&nbsp; يقوم الطبيب بمراقبتك عن كثب . سوف ينصحك الطبيب كيف يجب أن تبدأ في تناول فافيرين بمجرّد أن تتوقف عن تناول الأدوية من مجموعة MAOI.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول تيزانيدين، والذي يستخدم غالبا لإرخاء العضلات .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ترضعين طفلك رضاعة طبيعية .</p><p dir="RTL">يجب عدم تناول هذا الدواء إذا كان أي مما سبق ينطبق عليك . إذا لم تكن متأكدا ، تحدث مع طبيبك قبل تناول أقراص فافيرين .</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التحذيرات والاحتياطات:</strong></p><p dir="RTL">تحدث إلى طبيبك أو إلى الصيدلي قبل تناول أقراص فافيرين إذا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرّضت مؤخرا لنوبة قلبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ حاملاً، أو &nbsp;قد تكونين حاملا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;كنت تعاني من &nbsp;الصرع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ من مشاكل النزيف أو إذا كنت تستخدم بانتظام الأدوية التي تزيد من خطر النزيف ، مثل مسكنات الألم الشائعة&nbsp; أو في حالة الحمل (برجاء قراءة المعلومات الخاصة &quot;بالحمل&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;كنت تعاني من مرض السكري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتعالج بالصدمة الكهربائية (ECT)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرّضت في أي وقت مضى للهوس (شعور بالابتهاج أو الإثارة المفرطة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مشاكل في الكبد أو الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك ارتفاع في ضغط عينيك (جلوكوما)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت أقل من 18 سنة (انظر أيضا القسم 3 &quot;كيفية تناول فافيرين&quot;)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك ، سيخبرك طبيبك ما إذا كان من الآمن لك البدء في تناول فافيرين.</p><p dir="RTL">&nbsp;في بعض الأحيان، قد تراودك أفكار تؤدي للأرق (على سبيل المثال، يتعذّر عليك الجلوس أو الوقوف طويلاً (التململ) أو قد تزيد هذه الأفكار خلال الأسابيع القليلة الأولى من العلاج بفافيرين حتى يبدأ عمل الدواء وتأثيره المضاد للاكتئاب. اخبر طبيبك على الفور إذا واجهت هذه الأعراض إذ قد يرى أنه ينبغي&nbsp; تعديل الجرعة لك.</p><p dir="RTL">ومن الممكن أن يؤدي استخدامك فافيرين&reg; إلى ظهور طفح جلدي شديد. في حالة إصابتك بطفح جلدي أو التهاب في الأغشية المخاطية <strong>يجب عليك التوقف </strong>عن تناول الدواء في الحال والتوجه لطبيبك على الفور. ويشمل الطفح الجلدي الشديد ظهور تحسس يبدأ من الأطراف على جانبي&nbsp; الجسم بشكل طفيف ثم يبدأ في التطور على شكل دوائر مثل (داء الحمامي متعدد الأشكال)، كما ويمكن أن يشمل الطفح الجلدي ظهور بثور وتقشير في طبقات الجلد، خاصةً حول الفم والأنف والعينين والأعضاء التناسلية (متلازمة ستيفنز جونسون)، ومن الممكن أيضًا أن يتطور تقشير طبقات الجلد ليصل (لأكثر من 30٪ من سطح الجسم &ndash; والمعروف باسم انحلال البشرة النخري السمي).</p><p dir="RTL">&nbsp;قد تسبب الأدوية مثل فافيرين&reg; المعروفة باسم (SSRIs) عجز جنسي (انظر القسم 4)، وقد استمر هذا العجز بعد التوقف عن تناول الدواء في بعض الحالات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأفكار الانتحارية وتفاقم الاكتئاب أو حالات القلق</strong></p><p dir="RTL">إذا كنت تعاني من الاكتئاب و / أو لديك اضطرابات قلق يمكن أن &nbsp;تراودك أحيانا &nbsp;أفكار تدعوك للإضرار بنفسك أو قتل نفسك. من الممكن أن تزداد هذه الأعراض عند بدء العلاج بمضادات الاكتئاب ، وحيث أن جميع هذه الأدوية تستغرق وقتا للعمل وبدء التأثير ، عادة حوالي أسبوعين ولكن في بعض الأحيان تستغرق مدة أطول .</p><p dir="RTL">فقد تكون أكثر عرضة لأفكار مثل هذه:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك سابقا أفكار من الإضرار بنفسك أو قتل نفسك .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت من الشباب البالغين . حيث قد أظهرت معلومات من التجارب السريرية على زيادة خطر السلوك الانتحاري في البالغين والذين تقل أعمارهم عن 25 عاما ممن يعانون من مشكلات نفسية والذين يتلقون علاجا بالأدوية المضادة للاكتئاب .</p><p dir="RTL">إذا راودتك أفكار تدعوك للإضرار بنفسك أو قتل نفسك في أي وقت ، <strong>يجب عليك الاتصال بطبيبك أو الذهاب إلى المستشفى على الفور</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد تجد من المفيد أن تخبر أحد الأقارب أو الأصدقاء المقربين منك</strong> أنك مصاب بالاكتئاب أو لديك اضطراب قلق، واطلب منهم قراءة هذه النشرة . قد تطلب منهم أن يخبروك إذا كانوا يعتقدون أن الاكتئاب أو القلق لديك يزداد سوءا ، أو إذا كانوا قلقين بشأن التغييرات في سلوكك .</p><p dir="RTL"><strong>أخبر طبيبك على الفور </strong>إذا تعرّضت لأي أفكار أو تجارب مُقلقة.<br />&nbsp;</p><p dir="RTL"><strong>الاستخدام للأطفال والمراهقين الذين تقل أعمارهم عن 18 سنة</strong></p><p dir="RTL">يجب على الأطفال والمراهقين الذين تقل أعمارهم عن 18 عاما عدم تناول هذا الدواء ، إلا إذا كانوا يعالجون من OCD (اضطراب الوسواس القهري ، والأفكار الوسواسية و / أو السلوك القهري) .</p><p dir="RTL">وذلك لأن فافيرين لا يستخدم لعلاج الاكتئاب في الأشخاص الذين تقل أعمارهم عن 18 عاما .</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن استخدام هذا النوع من الأدوية من قِبل الأشخاص الذين تقل أعمارهم عن 18 عاما يُعرّضهم لخطر متزايد من حدوث الأعراض الجانبية مثل محاولة الانتحار، وأفكار عن الانتحار والعداء، مثل العدوان والسلوك المعارض والغضب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا وصف طبيبك فافيرين لشخص دون سن 18 عاما من العمر وكنت ترغب في مناقشة هذا الأمر معه، يرجى العودة إلى الطبيب. يجب عليك إخبار طبيبك عند ظهور أو تفاقم أيّ من الأعراض المذكورة أعلاه لدى المرضى الذين يتناولون فافيرين ممن تقل أعمارهم عن 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وكذلك لا يُعرف إلى الآن إذا كان استخدام فافيرين لمن هم دون سن 18 عاما يمكن أن يؤثر على النمو، والنضج أو تطور الذكاء أو السلوك على المدى الطويل لديهم.<br />&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>أدوية أخرى مع أقراص فافيرين</strong><strong>: </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت &nbsp;تتناول، أو قد &nbsp;تناولت مؤخرا أو ربما تتناول أي أدوية أخرى، بما في ذلك الأدوية التي تم صرفها دون وصفة طبية .</p><p dir="RTL">- يجب أن لا تبدأ في تناول العلاجات العشبية التي تحتوي على &nbsp;نبتة سانت جون أثناء علاجك بفافيرين لأن هذا قد يؤدي إلى زيادة الآثار غير المرغوب فيها . إذا كنت تتناول نبتة سانت جون بالفعل عندما تبدأ في العلاج بفافيرين، فيجب التوقف عن تناول نبتة سانت جون وأخبر طبيبك في زيارتك القادمة .</p><p dir="RTL">- إذا كنت تتناول دواء لعلاج الاكتئاب أو القلق خلال الأسبوعين الماضيين، أو كنت تعاني من مرض انفصام الشخصية ، تحقق مع طبيبك أو الصيدلي .</p><p dir="RTL">سيقوم طبيبك أو الصيدلي بالتحقق مما إذا كنت تتناول أدوية أخرى لعلاج الاكتئاب أو الحالات ذات الصلة ، قد تشمل هذه الأدوية ما يلي:</p><p dir="RTL">- البنزوديازيبينات</p><p dir="RTL">- مضادات الاكتئاب ثلاثية الحلقات</p><p dir="RTL">- &nbsp;مضادات&nbsp; الذهان</p><p dir="RTL">- الليثيوم</p><p dir="RTL">- التربتوفان</p><p dir="RTL">- مثبطات أوكسيداز أحادي الأمين (MAOI) مثل موكلوبيميد</p><p dir="RTL">- بيموزيد</p><p dir="RTL">- مثبطات &nbsp;استرجاع السيروتونين الانتقائية (SSRI) مثل سيتالوبرام</p><p dir="RTL">&nbsp;</p><p dir="RTL">طبيبك سوف يخبرك إذا كان الوقت مناسب وآمن للبدء بتناول فافيرين .</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك أيضا إخبار الطبيب أو الصيدلي <strong>إذا كنت تتناول أيًّا من الأدوية المذكورة أدناه:</strong></p><p dir="RTL">- الأسبرين (أستيل حمض الساليسيلك) أو الأدوية الشبيهة للأسبرين ، وتستخدم لعلاج الألم والتهاب (التهاب المفاصل)</p><p dir="RTL">- السيكلوسبورين ، وتستخدم للحد من نشاط الجهاز المناعي</p><p dir="RTL">- الميثادون ، يستخدم لعلاج الألم وأعراض الانسحاب</p><p dir="RTL">- مكسيليتين ، وتستخدم لعلاج اضطراب نظم القلب</p><p dir="RTL">- الفينيتوين أو الكاربامازيبين ، و &nbsp;يستخدمان لعلاج الصرع</p><p dir="RTL">- بروبرانولول ، ويستخدم لعلاج ارتفاع ضغط الدم وأمراض القلب</p><p dir="RTL">- روبينيرول ، يُستخدم لعلاج مرض باركنسون</p><p dir="RTL">- &quot;تريبتان&quot; ، وتستخدم هذه المجموعة لعلاج الصداع النصفي، مثل سوماتريبتان</p><p dir="RTL">- تيرفينادين، ويُستخدم لعلاج الحساسية . &nbsp;&nbsp;ينبغي عدم تناول فافيرين &nbsp;جنبا إلى جنب مع تيرفينادين</p><p dir="RTL">- &nbsp;سيلدينافيل، &nbsp;يُستخدم لعلاج ضعف الانتصاب</p><p dir="RTL">- الثيوفيلين، يستخدم لعلاج الربو والتهاب الشعب الهوائية</p><p dir="RTL">- الترامادول، وهو مسكن للآلام</p><p dir="RTL">- كلوبيدوغريل أو الوارفارين أونيكومالون أو أي دواء آخر يستخدم لمنع حدوث جلطات الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول أو تناولت مؤخرا أي من الأدوية في القائمة المذكورة أعلاه ولم تناقشها مع طبيبك ، فارجع إلى طبيبك &nbsp;واسأله عما يتوجب عليك فعله.&nbsp; &nbsp;&nbsp;قد تحتاج إلى تغيير الجرعة الخاصة بك أو قد تحتاج إلى أن تتناول دواء مختلفا .</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عليك أن تخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت فافيرين مع أي أدوية أخرى. ويشمل ذلك الأدوية التي تم تناولها دون وصفة طبية ، بما في ذلك الأدوية العشبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول </strong><strong>أقراص فافيرين مع الطعام والشراب: </strong></p><p dir="RTL">لا تشرب الكحول إذا كنت تتناول فافيرين . وذلك لأن الكحول &nbsp;يُعزز من تأثير فافيرين وسوف &nbsp;يجعلك تشعر بالنّعاس وعدم الاتزان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت &nbsp;تُكثر من شرب الشاي والقهوة والمشروبات الغازية التي تحتوي على الكافيين ، فقد &nbsp;تواجه أعراض مثل ارتعاش اليدين، والشعور بالمرض، وسرعة معدل ضربات القلب (الخفقان)، &nbsp;والتململ وصعوبة النوم (الأرق). إذا قمت &nbsp;بتقليل كمية الكافيين التي تشربها، قد تختفي هذه الأعراض .</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية:</strong></p><p dir="RTL">استشيري طبيبك أو الصيدلي قبل تناول أي دواء .</p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">هناك معلومات محدودة فقط فيما يتعلق باستخدام فلوفوكسامين خلال فترة الحمل . <strong><u>لا تتناولي فلوفوكسامين إذا كنتِ حاملا ما لم يقرر طبيبك أنه من الضروري للغاية لك. إذا كنت تتناولين حاليا فلوفوكسامين &nbsp;وتنوين الحمل أو الإنجاب بالنسبة للرجل، يرجى استشارة الطبيب &nbsp;ليقرر ما إذا كان دواء بديلا ضروري أو مناسب .</u></strong></p><p dir="RTL"><u>إذا كنت تتناول فلوفوكسامين في نهاية الحمل، فقد يكون هناك خطر متزايد بحدوث نزيف مهبلي شديد بعد الولادة بفترة وجيزة، خاصة إذا كان لديك تاريخ مرضي مع اضطرابات النزيف. لذا يجب أن يكون طبيبك أو الممرضة القابلة الخاصة بك على علم بأنك تتناول فلوفوكسامين حتى يتمكنوا من مساعدتك على أكمل وجه.</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أظهرت الدراسات التي أُجريت على الحيوانات أن تناول فلوفوكسامين يقلل من جودة الحيوانات المنوية. ومن الناحية النظرية، يمكن أن يؤثر ذلك على الخصوبة ، ولكن لم يلاحظ حتى الآن تأثير ذلك على الخصوبة لدى البشر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;تأكدي من أن الممرضة القابلة&nbsp; و / أو الطبيب على علم بأنكِ تتناولين فلوفوكسامين. &nbsp;إن تناول بعض الأدوية مثل فلوفوكسامين أثناء الحمل ، وخاصة في الأشهر الثلاثة الأخيرة من الحمل، قد يزيد من خطر حدوث حالة خطيرة في الأطفال، تسمى ارتفاع ضغط الدم الرئوي المستمر (PPHN)، مما يجعل الطفل يتنفس بشكل أسرع ويظهر بلون كالأزرق . وعادة ما تبدأ هذه الأعراض خلال ال 24 ساعة الأولى بعد ولادة الطفل . إذا حدث ذلك لطفلك ، يجب عليك الإتصال &nbsp;بالممرضة القابلة و / أو الطبيب فورا .</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك عدم التوقف عن العلاج بتناول فلوفوكسامين بشكل مفاجئ . أخبرى طبيبك إذا كنت تتناولين فلوفوكسامين خلال الأشهر الثلاثة الأخيرة من الحمل ، إذ قد يعاني طفلك عند ولادته من بعض الأعراض الأخرى بالإضافة إلى صعوبة في التنفس أو زرقة الجلد، مثل عدم القدرة على النوم أو الرضاعة بشكل ملائم، وقد يبدو أكثر برودة أو أكثر سخونة، ويبدو عليه الإعياء، ويُكثر من البكاء، مع تيبّس العضلات أو نقص التوتر العضلي، والخمول والنعاس والرعاش، الانفعال العصبي أو النوبات. إذا عانى طفلكِ من أي من هذه الأعراض عند ولادته اتصلي بطبيبك فورا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">فلوفوكسامين يمر في حليب الثدي . لذا هناك خطر من التأثير على الطفل . ولذلك، يجب عليك مناقشة الأمر مع طبيبك . و سوف يقرر ما إذا كان يجب عليك التوقف عن الرضاعة الطبيعية أو وقف العلاج مع فلوفوكسامين . لا توجد أي معلومات حول ما إذا كان فلوفوكسامين يؤثر على إنتاج الحليب لدى الأم أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات: </strong></p><p dir="RTL">يمكنك القيادة واستخدام الآلات أثناء تناول فافيرين ، طالما أن هذا الدواء لا يجعلك تشعر بالنعاس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>يحتوي فافيرين على الصوديوم</u></strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول من الصوديوم، حيث يحتوي كل قرص على (23 ملغم) من الصوديوم فقط، وهذا يعني أنه &quot;خالي من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الجرعة<br />تناول هذا الدواء دائمًا كما وصفه لك الطبيب تمامًا، استشر طبيبك أو الصيدلي إن لم تكن متأكداً .</p><p dir="RTL">&nbsp;</p><p dir="RTL">جرعة البداية المعتادة للبالغين (18 سنة فما فوق):</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>علاج الاكتئاب:</u></p><p dir="RTL">- يتم البدء بتناول 50 أو 100 ملغم يوميا، مساء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>علاج اضطراب الوسواس القهري:</u></p><p dir="RTL">يتم البدء بتناول 50 ملغم يوميا، ويفضل مساء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تبدأ في الشعور بالتحسن بعد بضعة أسابيع ، فتحدث إلى طبيبك ليقدم لك المشورة. قد يقررطبيبك زيادة الجرعة تدريجياً.</p><p dir="RTL">الجرعة اليومية القصوى الموصى بها هي 300 ملغم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا نصحك الطبيب أن تتناول أكثر من 150 ملغم يوميا<strong>، لا تتناول الأقراص في آن واحد</strong> . &nbsp;اسأل طبيبك عن التوقت الأمثل لتناولها.</p><p dir="RTL"><strong>الجرعة المعتادة للأطفال والمراهقين الذين يعانون من اضطراب الوسواس القهري - </strong><strong>OCD</strong><strong> (8 سنوات فما فوق):</strong></p><p dir="RTL">ابدأ بتناول 25 &nbsp;ملغم (نصف قرص) يوميا، ويفضل تناول الدواء قبل النوم. و قد يزيد طبيبك الجرعة كل 4-7 أيام &nbsp;بمقدار25 &nbsp;ملغم حسب تحمّلك حتى يتم تحقيق الجرعة فعالة.</p><p dir="RTL">أعلى جرعة يومية هي 200 &nbsp;ملغم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا نصحك الطبيب أن تتناول أكثر من 50 ملغم يوميا، <strong>فلا تتناول الأقراص جميعها في آن واحد؛ </strong>اسأل طبيبك عن التوقت الأمثل لتناولها. إذا لم يتم تقسيم الجرعة بالتساوي ، ينبغي تناول الجرعة الأكبر في المساء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب على الأطفال والمراهقين الذين تقل أعمارهم عن 18 عاما عدم تناول هذا الدواء لعلاج الاكتئاب . يجب أن يوصف هذا الدواء للأطفال أو المراهقين لعلاج&nbsp; اضطراب &nbsp;الوسواس القهري (OCD) فقط .</p><p dir="RTL"><strong>طريقة تناول فافيرين</strong></p><p dir="RTL">يجب ابتلاع الأقراص مع كوب من الماء . لاينبغي مضغ الأقراص .</p><p dir="RTL">يمكنك كسر القرص إلى نصفين وذلك إذا نصحك الطبيب بذلك .</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;<strong>متى يبدأ تأثير الدواء</strong></p><p dir="RTL">قد يستغرق فافيرين بعض الوقت ليظهر تأثيره وفعاليته. بعض المرضى لا يشعرون بأنهم على ما يرام في أول 2 أو 3 أسابيع من العلاج .</p><p dir="RTL">استمر في تناول الأقراص حتى يخبرك الطبيب بأن تتوقف . &nbsp;قد يرغب طبيبك في أن تستمر في تناول أقراص فافيرين لبعض الوقت، لمدة 6 أشهر على الأقل حتى وإن كنت تشعر بتحسّن،&nbsp; للتأكد من أن الدواء قد عمل بفعالية تامة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتوقف عن</strong> تناول فافيرين بشكل مفاجئ &nbsp;لأنك قد تعاني <strong>من أعراض انسحاب</strong> مثل :</p><p dir="RTL">- الإثارة والقلق</p><p dir="RTL">- الارتباك</p><p dir="RTL">- إسهال</p><p dir="RTL">- صعوبة النوم/ أحلام مزعجة</p><p dir="RTL">- الدوخة</p><p dir="RTL">- عدم الاستقرار العاطفي</p><p dir="RTL">- الصداع</p><p dir="RTL">- &nbsp;الهيجان</p><p dir="RTL">- الغثيان و / أو التقيؤ</p><p dir="RTL">- الخفقان (سرعة في ضربات القلب)</p><p dir="RTL">- الاضطراب الحسي (مثل الأحاسيس بالصدمة الكهربائية أو الاضطرابات البصرية)</p><p dir="RTL">- التعرق</p><p dir="RTL">- الارتعاش</p><p dir="RTL">&nbsp;عند توقفك عن تناول فافيرين، سوف يساعدك طبيبك على تقليل الجرعة ببطء على مدى عدة أسابيع أو شهور . وهذا من شأنه أن يساعد على تقليل فرصة حدوث أعراض الانسحاب . معظم الناس يجدون أن أعراض الإنسحاب بسبب &nbsp;التوقف عن تناول فافيرين خفيفة وتختفي تلقائيا في غضون أسبوعين. ولكن بالنسبة للبعض الآخر، قد تكون هذه الأعراض أكثر شدة، أو قد تستمر لفترة أطول .</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا عانيت من أعراض الانسحاب مع التناقص التدريجي لجرعة فافيرين فسوف يقرر طبيبك أن تتوقف عن تناول العلاج ببطء أكثر. إذا عانيت من أعراض انسحاب شديدة&nbsp; مع التناقص التدريجي لجرعة فافيرين، يرجى مراجعة الطبيب. قد يطلب منك طبيبك العودة إلى تناول أقراصك مرة أخرى ثم تتوقف عن تناولها ببطء أكثر (انظر القسم 4 &quot;الأعراض الجانبية المحتملة&quot;) .</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا واجهت أي أعراض عند إيقاف العلاج، اتصل بطبيبك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من أقراص &nbsp;فافيرين:</strong></p><p dir="RTL">إذا تناولت أنت أو شخص آخر جرعة زائدة من فافيرين (جرعة زائدة) ، تحدث مع طبيب أو قم بالذهاب إلى المستشفى على الفور . ويجب أن تأخذ عبوة الدواء معك .</p><p dir="RTL">&nbsp;</p><p dir="RTL">أعراض الجرعة الزائدة تشمل لكن لا يقتصرعلى&nbsp; للتالي : الغثيان والقيء والإسهال والشعور بالنعاس أو بالدوار . كما تم الإبلاغ عن حالات قلبية (بطء أو سرعة ضربات القلب ، وانخفاض ضغط الدم) ، ومشاكل في الكبد وتشنجات (نوبات) وغيبوبة، ولكن قد تظهر عليك أعراض أخرى غير مذكورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول </strong><strong>إحدى جرعات أقراص </strong><strong>فافيرين:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت أن تتناول جرعة من الأقراص، تخطي تلك الجرعة الفائتة ثم تناول الجرعة التالية في موعدها .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية .</p><p dir="RTL">إذا كان لديك أية أسئلة أخرى حول هذا المنتج واستخدامه اسأل طبيبك أو الصيدلي .</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يتسبب هذا الدواء في آثار جانبية ، على الرغم من أنها لا تؤثر في الجميع .<br />معدلات الإصابة بالآثار الجانبية معرفة كما يلي :</p><table border="1" cellspacing="1" cellpadding="0" style="width:501px"><tbody><tr><td><p dir="RTL">شائعة جدا</p></td><td><p dir="RTL">قد تصيب أكثر من شخص من أصل 10 أشخاص</p></td></tr><tr><td><p dir="RTL">شائعة</p></td><td><p dir="RTL">قد تصيب من شخص إلى 10 أشخاص من أصل 100 شخص</p></td></tr><tr><td><p dir="RTL">غير شائعة</p></td><td><p dir="RTL">قد تصيب من شخص إلى 10 أشخاص من أصل 1000 شخص</p></td></tr><tr><td><p dir="RTL">نادرة</p></td><td><p dir="RTL">قد تصيب من شخص إلى 10 أشخاص من أصل 10000 شخص</p></td></tr><tr><td><p dir="RTL">نادرة جدا</p></td><td><p dir="RTL">قد تصيب أقل من شخص إلى من أصل 10000 شخص</p></td></tr><tr><td><p dir="RTL">غير معلومة</p></td><td><p dir="RTL">لا يمكن تقدير معدلاتها من خلال البيانات المتاحة</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية المرتبطة بتناول هذا النوع من الدواء</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد &nbsp;ترد أحيانا <strong>أفكار &nbsp;حول الانتحار أو &nbsp;إيذاء النفس</strong> أو قد تزيد في الأسابيع القليلة الأولى من العلاج بتناول فافيرين ، حتى يبدأ تأثير الدواء المضاد للاكتئاب بالعمل .</p><p dir="RTL"><strong>&nbsp;اتصل بطبيبك على الفور إذا </strong>تعرّضت لأيّ أفكار أو تجارب مُقلقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;<strong>إذا واجهت عدة أعراض في نفس الوقت</strong> قد يكون لديك واحدة من الحالات النادرة التالية :</p><p dir="RTL">- متلازمة السيروتونين: إذا كان لديك &nbsp;تعرّق، و تصلّب العضلات أو &nbsp;تقلصها ، وعدم الاستقرار، و ارتباك، ، &nbsp;وانفعال وهيجان شديد.</p><p dir="RTL">- المتلازمة الخبيثة&nbsp;للدواء المضاد&nbsp;للذهان: إذا كان لديك تصلب في العضلات، وارتفاع في درجة الحرارة، والارتباك وغيرها من الأعراض ذات الصلة .</p><p dir="RTL">متلازمة اضطراب الهرمون المضاد لإدرار البول SIADH : إذا كنت تشعر بالتعب، أو تشعر بالضعف أو الارتباك أو الألم، &nbsp;وتيبّس في العضلات مع عدم القدرة على التحكم بها.</p><p dir="RTL">. ويشمل التفاعل الجلدي الشديد ظهور طفح جلدي, يبدأ من الأطراف على جانبي&nbsp; الجسم بشكل طفيف ثم يبدأ في التطور على شكل دوائر مثل (داء الحمامي متعدد الأشكال)، كما ويمكن أن يشمل الطفح الجلدي ظهور بثور وتقشير في طبقات الجلد، خاصةً حول الفم والأنف والعينين والأعضاء التناسلية (متلازمة ستيفنز جونسون)، ومن الممكن أيضًا أن يتطور تقشير طبقات الجلد ليصل (لأكثر من 30٪ من سطح الجسم &ndash; المعروف باسم انحلال البشرة النخري السمي). ويظل تطور هذه الآثار الجانبية غير معروف (لا يمكن تقديره من البيانات المتاحة).</p><p dir="RTL"><strong>توقف عن تناول فافيرين واتصل بطبيبك فورا</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;إذا ظهرت بقع أو كدمات أرجوانية غير عادية على جلدك أو كنت تتقيئ الدم أو تمرير دم مع البراز ، اتصل بطبيبك للحصول على المشورة .</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;إن التوقف عن تناول فلوفوكسامين (خاصة بشكل مفاجئ) عادة ما يؤدي إلى أعراض الانسحاب (انظر &quot;أعراض الانسحاب&quot; في القسم 3).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أحيانا يشعر المرضى بالإعياء قليلا &nbsp;حين يبدأ فافيرين في العمل . على الرغم من أن الشعور بالإعياء غير سار، &nbsp;إلا أن هذه الأعراض تختفي &nbsp;بسرعة مع الإستمرار في تناول الأقراص كما هو محدد . قد يستغرق هذا بضعة أسابيع .</p><p dir="RTL"><strong>الآثار الجانبية المرتبطة بتناول فافيرين</strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة:</strong></p><p dir="RTL">- &nbsp;الهيجان</p><p dir="RTL">- القلق</p><p dir="RTL">- الإمساك</p><p dir="RTL">- إسهال</p><p dir="RTL">- صعوبة النوم</p><p dir="RTL">- الدوخة</p><p dir="RTL">- جفاف الفم</p><p dir="RTL">- سرعة ضربات القلب</p><p dir="RTL">- الشعور بالنعاس (الخمول)</p><p dir="RTL">- الشعور بالتوعك (الشعور بالضيق)</p><p dir="RTL">- صداع الراس</p><p dir="RTL">- عسر الهضم</p><p dir="RTL">- فقدان الشهية</p><p dir="RTL">- العصبية</p><p dir="RTL">- آلام في المعدة</p><p dir="RTL">- التعرق</p><p dir="RTL">- رعشه</p><p dir="RTL">- ضعف العضلات (الوهن)</p><p dir="RTL">- القيء</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة:</strong></p><p dir="RTL">- رد فعل تحسسي على الجلد (بما في ذلك تورم الوجه ، الشفة أو اللسان ، الطفح الجلدي أو الحكة)</p><p dir="RTL">- الارتباك</p><p dir="RTL">- تأخير القذف</p><p dir="RTL">- الدوخة عند الوقوف بسرعة كبيرة جدا</p><p dir="RTL">- الهلوسة</p><p dir="RTL">- &nbsp;فقدان التناسق الحركي</p><p dir="RTL">- آلام العضلات أو المفاصل</p><p dir="RTL">- السلوك العدواني</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية نادرة:</strong></p><p dir="RTL">- التشنجات</p><p dir="RTL">- مشاكل بالكبد</p><p dir="RTL">-&nbsp; الشعور بالابتهاج أو الإثارة المفرطة</p><p dir="RTL">- الحساسية لأشعة الشمس</p><p dir="RTL">- تدفق غير متوقع للحليب</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى المبلغ عنها:</strong></p><p dir="RTL">- التملل (الأرق)</p><p dir="RTL">- خلل في التذوق</p><p dir="RTL">- &nbsp;فقد الإرجاز (الفشل في تحقيق النشوة الجنسية)</p><p dir="RTL">- للمرضى الإناث: اضطرابات في الحيض (النزيف الشهري)</p><p dir="RTL">- نزيف مهبلي غزير بعد وقت قصير من الولادة (نزيف ما بعد الولادة)، أنظري الحمل (قسم 2) لمزيد من المعلومات</p><p dir="RTL">&nbsp;</p><p dir="RTL">- اضطرابات التبول (مثل &nbsp;كثرة الحاجة للتبول خلال النهار و / أو الليل، والافتقار المفاجئ للسيطرة على التبول خلال النهار و / أو الليل، أو عدم القدرة على التبول)</p><p dir="RTL">- تنميل (وخز أو خدر)</p><p dir="RTL">&nbsp;- الجلوكوما (زيادة الضغط في العين)</p><p dir="RTL">- اتساع حدقة العين</p><p dir="RTL">- زيادة في مستوى هرمون البرولاكتين (هرمون يدعم إنتاج الحليب في الأم المرضعة)</p><p dir="RTL">- تغيرات في الوزن</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">وقد لوحظ وجود خطر متزايد من كسور العظام في المرضى الذين يتناولون هذا النوع من الدواء .</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية ذات الصلة لعلاج الوسواس القهري ، في الأطفال والمراهقين (لا تتوافر معلومات عن تواتر حدوثها):</strong></p><p dir="RTL">&nbsp;- الهوس الخفيف (الشعور بالابتهاج والإثارة المُفرطة)</p><p dir="RTL">- الهيجان</p><p dir="RTL">- التشنجات</p><p dir="RTL">- صعوبة النوم (الأرق)</p><p dir="RTL">- نقص الطاقة (الوهن)</p><p dir="RTL">- فرط النشاط (فرط الحركة)</p><p dir="RTL">- الشعور بالنعاس (فرط النوم)</p><p dir="RTL">- عسر الهضم</p><p dir="RTL">إذا زادت حدة أي من هذه الأعراض الجانبية ، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة ، يرجى إبلاغ الطبيب المعالج أو الصيدلي .. بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء .</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية (</strong><strong>NPC</strong><strong>)</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-11-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال: 19999</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">&bull; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم .<br />&bull; لا يخدن في درجة حرارة أعلى من 25 درجة مئوية .<br />&bull; فترة الصلاحية: 3 سنوات<br />&bull; لا تستخدم فافيرين أقراص بعد انتهاء تاريخ الصلاحية المذكور على العبوة الخارجية . تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من ذلك<br />الشهر .<br />&bull; لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أو عن طرياق النفاياات المنزلية . اسأل الصيدلي عن كيفية التخلص من الأدوية<br />التي لم تعد مطلوبة . هذه التدابير تساعد في الحفاظ على البيئة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ما تحويه علبة فافيرين أقراص:</p><p dir="RTL">&bull; المادة الفعالة هي فلوفوكسامين مالييات . حيث يحتوي كل قرص على 50 ملجم أو 100 ملجم من فلوفوكسامين مالييات .</p><p dir="RTL">&bull; الصواغات الأخرى هي السليلوز مانيتول (E421)&nbsp;نشاا الذرة ، النشاء قبل التجلتن ، صوديوم السيليكا الغروية اللامائية ، هايبروميلوز ،</p><p dir="RTL">غليكول البوليثينيل 6000 ، التلك وثاني أكسيد التيتانيوم (E171)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ما هو شكل فافيرين أقراص ومحتويات العلبة؟</p><p dir="RTL">فافيرين أقراص 50 ملجم عبارة عن أقراص مستديرة ، مغطاة بطبقة رقيقة ذات اللون الأبيض إلى الأبيض القاتم . محفور عليها رقم( 291)&nbsp;على<br />جانبي حز&nbsp;التقسيم .</p><p dir="RTL">فافيرين أقراص 100 ملجم عبارة عن أقراص بيضاوية ، مغطاة بطبقة رقيقة ذات اللون الأبيض إلى الأبيض القاتم . محفور عليها رقم 313<br />على جانبي حد التقسيم .</p><p dir="RTL">تحتوي كل عبوة فافيرين أقراص 50 ملجم على 5, 10, 20, 30, 50, 60, 90, 100و 250 قرص</p><p dir="RTL">&nbsp;تحتوي كل عبوة فافيرين أقراص 100 ملجم على 15, 20, 30, 50, 60, 90, 100, 120, 250 قرص</p><p>قد لا تتوفر كافة العبوات في السوق .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">صاحب حق التسويق:<br />أبوت هيلث كير برودكتس بي. في.<br />هولاندا<br />المصنع:<br />مايلان لابوراتوريد إس أ إس<br />٠١٤٠٠ شاتيلون سور شارالاون ، فرنسا<br />تغليف:</p><p>شركة اجا للصناعات الدوائية المحدودة (اجا فارما)<br />حائل ٥٥٤١٤ ، المدينة الصناعية &ndash; حائل<br />المملكة العربية السعودية.<br />جده - المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سيبتمبر 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fevarin® 50, film-coated tablets
Fevarin® 100, film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 50 mg or 100 mg of fluvoxamine maleate.
For a full list of excipients, see 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet
Faverin 50:
Round, biconvex, white to off-white film coated tablets. With '291' on both sides of the score in mirror image.
Faverin 100:
Oval, biconvex, white to off-white scored film-coated tablets. With '313' on both sides of the score in mirror image.

The tablet can be divided into equal halves.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Major depressive episode<br />- Obsessive Compulsive Disorder (OCD)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Depression</u> </em></p><p><em>Adults</em></p><p>The recommended dose is 100 mg daily. Patients should start on 50 or 100 mg, given as a single dose in the evening. Dosage should be reviewed and adjusted if necessary within 3 to 4 weeks of initiation of therapy and thereafter as judged clinically appropriate. Although there may be an increased potential for undesirable effects at higher doses, if after some weeks on the recommended dose insufficient response is seen some patients may benefit from having their dose increased gradually up to a maximum of 300 mg a day (see section 5.1). Doses up to 150 mg can be given as a single dose, preferably in the evening. It is advisable that a total daily dose of more than 150 mg is given in 2 or 3 divided doses. Dosage adjustments should be made carefully on an individual patient basis, to maintain the patients at the lowest effective dose.</p><p>&nbsp;</p><p>Patients with depression should be treated for a sufficient period of at least 6 months to ensure that they are free from symptoms.</p><p><em>Children/adolescents</em></p><p>Faverin should not be used in children and adolescents under the age of 18 years for the treatment of major depressive episode. The efficacy and safety of Faverin have not been established in the treatment of paediatric major depressive episode (see section 4.4).</p><p>&nbsp;</p><p><em><u>Obsessive Compulsive Disorder</u> </em></p><p><em>Adults</em></p><p>The recommended dose is between 100-300 mg daily. Patients should start at 50 mg per day. Although there may be an increased potential for undesirable effects at higher doses, if after some weeks on the recommended dose insufficient response is seen some patients may benefit from having their dose increased gradually up to maximum of 300 mg a day (see section 5.1). Doses up to 150 mg can be given as a single dose, preferably in the evening. It is advisable that a total daily dose of more than 150 mg is given in 2 or 3 divided doses. If a good therapeutic response has been obtained, treatment can be continued at a dosage adjusted on an individual basis.</p><p>&nbsp;</p><p>While there are no systematic studies to answer the question of how long to continue fluvoxamine treatment, OCD is a chronic condition and it is reasonable to consider continuation beyond 10 weeks in responding patients. Dosage adjustments should be made carefully on an individual patient basis, to maintain the patients at the lowest effective dose. The need for treatment should be reassessed periodically. Some clinicians advocate concomitant behavioural psychotherapy for patients who have done well on pharmacotherapy. Long-term efficacy (more than 24 weeks) has not been demonstrated in OCD.</p><p>&nbsp;</p><p><em>Children/adolescents</em></p><p>In children over 8 years and adolescents there is limited data on a dose of up to 100 mg b.i.d for 10 weeks. The starting dose is 25 mg per day. Increase every 4-7 days in 25 mg increments as tolerated until an effective dose is achieved. The maximum dose in children should not exceed 200 mg/day. (For further details see section 5.1 and 5.2). It is advisable that a total daily dose of more than 50 mg should be given in two divided doses. If the two divided doses are not equal, the larger dose should be given at bedtime.</p><p>&nbsp;</p><p><em>Withdrawal symptoms seen on discontinuation of fluvoxamine</em></p><p>Abrupt discontinuation should be avoided. When stopping treatment with fluvoxamine the dose should be gradually reduced over a period of at least one or two weeks in order to reduce the risk of withdrawal reactions (see section 4.4 4.8). If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered.</p><p>Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p><p>&nbsp;</p><p><em>Hepatic or renal insufficiency</em></p><p>Patients suffering from hepatic or renal insufficiency should start on a low dose and be carefully monitored.</p><p>&nbsp;</p><p><em>Method of administration</em></p><p>Fluvoxamine tablets should be swallowed with water and without chewing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Faverin tablets are contraindicated in combination with tizanidine and monoamine oxidase inhibitors (MAOIs) (see section 4.4 and 4.5).

Treatment with fluvoxamine can be initiated:
-	two weeks after discontinuation of an irreversible MAOI, or
-	the following day after discontinuation of a reversible MAOI (e.g. moclobemide, linezolid).

At least one week should elapse between discontinuation of fluvoxamine and initiation of therapy with any MAOI.

See section 4.4 for precautions in the exceptional case linezolid needs to be given in combination with fluvoxamine.

Faverin tablets should not be used in combination with pimozide (see section 4.5). Hypersensitivity to the active substance or to any of the excipients.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Suicide/suicidal thoughts or clinical worsening</em></p><p>Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p>&nbsp;</p><p>Other psychiatric conditions for which Faverin is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.</p><p>&nbsp;</p><p>Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment.</p><p>&nbsp;</p><p><em>Young adults (ages 18 to 24 years)</em></p><p>A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.</p><p>&nbsp;</p><p>Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes.</p><p>&nbsp;</p><p>Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>Fluvoxamine should not be used in the treatment of children and adolescents under the age of 18 years, except for patients with Obsessive Compulsive Disorder. Suicide- related behaviours (suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms.</p><p>&nbsp;</p><p>In addition, long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are lacking.</p><p>&nbsp;</p><p><em>Geriatric population</em></p><p>Data in elderly subjects give no indication of clinically significant differences in normal daily dosages compared to younger subjects. However, upward dose titration should be done slower in the elderly, and dosing should always be done with caution.</p><p>&nbsp;</p><p><em>Renal and hepatic impairment</em></p><p>Patients suffering from hepatic or renal insufficiency should start on a low dose and be carefully monitored.</p><p>&nbsp;</p><p>Treatment with fluvoxamine has rarely been associated with an increase in hepatic enzymes, generally accompanied by clinical symptoms. In such cases treatment should be discontinued.</p><p>&nbsp;</p><p><em>Withdrawal symptoms seen on discontinuation of fluvoxamine treatment </em>Withdrawal symptoms when treatment is discontinued are common, particularly if discontinuation is abrupt (see section 4.8). In clinical trials, adverse events seen on treatment discontinuation occurred in approximately 12% of patients treated with fluvoxamine, which is similar to the incidence seen in patients taking placebo. The risk of withdrawal symptoms may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction.</p><p>&nbsp;</p><p>The most commonly reported symptoms in association with withdrawal of the product include: dizziness, sensory disturbances (including paraesthesia, visual disturbances and electric shock sensations), sleep disturbances (including insomnia and intense dreams), agitation, irritability, confusion, emotional instability, headache, nausea and/or vomiting and diarrhoea, sweating and palpitations, tremor, and anxiety (see Section 4.8).</p><p>&nbsp;</p><p>Generally these events are mild to moderate; however, in some patients they may be severe in intensity. They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose.</p><p>&nbsp;</p><p>Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that fluvoxamine should be gradually tapered when discontinuing treatment over a period of several weeks or months, according to the patient&rsquo;s needs (see Section 4.2).</p><p><em>&nbsp;</em></p><p><em>Psychiatric Disorders</em></p><p>Fluvoxamine should be used with caution in patients with a history of mania/hypomania. Fluvoxamine should be discontinued in any patient entering a manic phase.</p><p>&nbsp;</p><p><em>Akathisia/psychomotor restlessness</em></p><p>The use of fluvoxamine has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</p><p>&nbsp;</p><p><em>Nervous system disorders</em></p><p>Although in animal studies fluvoxamine has no pro-convulsive properties, caution is recommended when the drug is administered to patients with a history of convulsive disorders. Fluvoxamine should be avoided in patients with unstable epilepsy and patients with controlled epilepsy should be carefully monitored. Treatment with fluvoxamine should be discontinued if seizures occur or if seizure frequency increases.</p><p>&nbsp;</p><p>On rare occasions, development of a serotonin syndrome or neuroleptic malignant syndrome-like events have been reported in association with treatment of fluvoxamine, particularly when given in combination with other serotonergic and/or neuroleptic drugs. As these syndromes may result in potentially life-threatening conditions, treatment with fluvoxamine should be discontinued if such events (characterised by clusters of symptoms such as hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes including confusion, irritability, extreme agitation progressing to delirium and coma) occur and supportive symptomatic treatment should be initiated.</p><p>In exceptional circumstances, linezolid (an antibiotic which is a reversible relatively weak non-selective MAOI) can be given in combination with fluvoxamine provided that there are facilities for close observation and management of symptoms of serotonin syndrome and monitoring of blood pressure (see section 4.3 and 4.5). If symptoms occur, physicians should consider discontinuing one or both agents.</p><p>&nbsp;</p><p><em>Metabolism and nutrition disorders</em></p><p>As with other SSRIs, hyponatraemia has been rarely reported, and appears to be reversible when fluvoxamine is discontinued. Some cases were possibly due to the syndrome of inappropriate antidiuretic hormone secretion. The majority of reports were associated with older patients.</p><p>Glycaemic control may be disturbed (i.e., hyperglycaemia, hypoglycaemia, decreased glucose tolerance), especially in the early stages of treatment. When fluvoxamine is given to patients with a known history of diabetes mellitus, the dosage of anti-diabetic drugs may need to be adjusted.</p><p>&nbsp;</p><p><em>Eye Disorders</em></p><p>Mydriasis has been reported in association with SSRIs such as fluvoxamine. Therefore caution should be used when prescribing fluvoxamine in patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma.</p><p>&nbsp;</p><p><em>Haematological disorders</em></p><p>There have been reports of the following haemorrhagic disorders: gastrointestinal bleeding, gynaecological haemorrhage, SSRIs may increase the risk of postpartum (see section 4.6 4.8). and other cutaneous or mucous bleeding with SSRIs. Caution is advised in patients taking SSRIs particularly in elderly patients and in patients who concomitantly use drugs known to affect platelet function (e.g. atypical antipsychotics and phenothiazines, most TCAs, acetylsalicylic acid, NSAIDs) or drugs that increase risk of bleeding as well as in patients with a history of bleeding and in those with predisposing conditions (e.g. thrombocytopenia or coagulation disorders).</p><p>&nbsp;</p><p><em>Cardiac disorders</em></p><p>Fluvoxamine should not be co-administered with terfenadine, astemizole or cisapride as plasma concentrations may be increased resulting in a higher risk for QT- prolongation/Torsade de Pointes.</p><p>&nbsp;</p><p>Due to lack of clinical experience, special attention is advised in the situation of post- acute myocardial infarction.</p><p>&nbsp;</p><p><em>Dermatological effects</em></p><p>Serious skin reactions, some of them fatal, including erythema multiforme, Stevens- Johnson syndrome and toxic epidermal necrolysis, have been reported in association with Fluvoxamine (see section 4.8). Patients appear to be at highest risk of these reactions early in the course of therapy. If skin reactions occur, fluvoxamine should be discontinued immediately, and the patient should be closely monitored.</p><p>&nbsp;</p><p><em>Electroconvulsive therapy (ECT)</em></p><p>There is limited clinical experience of concomitant administration of fluvoxamine and ECT therefore caution is advisable.</p><p>&nbsp;</p><p><em>Sexual dysfunction</em></p><p>Selective serotonin reuptake inhibitors (SSRIs) may cause symptoms of sexual dysfunction (see section 4.8). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs.</p><p>&nbsp;</p><p><em>CYP 2C19 inhibition</em></p><p>Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of fluvoxamine that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel. The clinical relevance of this interaction is uncertain. As a precaution concomitant use of fluvoxamine should be discouraged (see section 4.5).</p><p>&nbsp;</p><p><em>Information related to excipients</em></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pharmacodynamic interactions</u></em></p><p>The serotonergic effects of fluvoxamine may be enhanced when used in combination with other serotonergic agents (including tramadol, triptans, linezolid, SSRIs and St. John&acute;s Wort preparations) (See also section 4.4).</p><p>Fluvoxamine has been used in combination with lithium in the treatment of severely ill, drug-resistant patients. However, lithium (and possibly also tryptophan) enhances the serotonergic effects of fluvoxamine. The combination should be used with caution in patients with severe, drug-resistant depression.</p><p>&nbsp;</p><p>In patients on oral anticoagulants and fluvoxamine, the risk for haemorrhage may increase and these patients should therefore be closely monitored.</p><p>&nbsp;</p><p>As with other psychotropic drugs patients should be advised to avoid alcohol use while taking fluvoxamine.</p><p>&nbsp;</p><p><em><u>Monoamine oxidase inhibitors</u></em></p><p>Fluvoxamine should not be used in combination with MAOIs, including linezolid, due to risk of serotonin syndrome (see also section 4.3 and 4.4).</p><p>&nbsp;</p><p><em><u>Effect of fluvoxamine on the oxidative metabolism of other drugs</u></em></p><p>Fluvoxamine can inhibit the metabolism of drugs metabolized by certain cytochrome P450 isoenzymes (CYPs). A strong inhibition of CYP1A2 and CYP 2C19 is demonstrated in <em>in vitro </em>and <em>in vivo </em>studies. CYP2C9, CYP 2D6 and CYP3A4 are inhibited to a lesser extent. Drugs which are largely metabolised via these isoenzymes may have higher plasma concentrations of the active substance/metabolite when co- administered with Fluvoxamine.</p><p>&nbsp;</p><p>In case of prodrugs like clopidogrel, which are activated by CYPs mentioned above, plasma concentrations of the active substance/metabolite may be lower when co- administered with fluvoxamine. As a precaution concomitant use of clopidogrel and fluvoxamine should be discouraged.</p><p>&nbsp;</p><p>Concomitant therapy of fluvoxamine and these drugs should be initiated at or adjusted to the low end of their dose range. Plasma concentrations, effects or adverse effects of co-administered drugs should be monitored and their dosage should be reduced, if necessary. This is particularly relevant for drugs with a narrow therapeutic index.</p><p>&nbsp;</p><p><em><u>Compounds with narrow therapeutic index</u></em></p><p>Co-administration of fluvoxamine and drugs with a narrow therapeutic index (such as tacrine, theophylline, methadone, mexiletine, phenytoin, carbamazepine and cyclosporine) should be carefully monitored when these drugs are metabolized exclusively or by a combination of CYPs inhibited by fluvoxamine.</p><p>&nbsp;</p><p>If necessary, dose adjustment of these drugs is recommended.</p><p>&nbsp;</p><p>Due to the narrow therapeutic index of pimozide and its known ability to prolong QT interval, concomitant use of pimozide and fluvoxamine is contraindicated- see section 4.3.</p><p>&nbsp;</p><p>An increase in previously stable plasma levels of those tricyclic antidepressants (e.g. clomipramine, imipramine, amitriptyline) and neuroleptics (e.g. clozapine, olanzapine, quetiapine) which are largely metabolised through cytochrome P450 1A2 when given together with fluvoxamine, has been reported. A decrease in the dose of these products should be considered if treatment with fluvoxamine is initiated.</p><p>&nbsp;</p><p>The plasma levels of oxidatively metabolised benzodiazepines (e.g. triazolam, midazolam, alprazolam, and diazepam) are likely to be increased when co- administered with fluvoxamine. The dosage of these benzodiazepines should be reduced during co-administration with fluvoxamine.</p><p>As plasma concentrations of ropinirole may be increased in combination with fluvoxamine thus increasing the risk of overdose, surveillance and reduction in the</p><p>&nbsp;</p><p>dosage of ropinirole during fluvoxamine treatment and after its withdrawal may be required.</p><p>&nbsp;</p><p>As plasma concentrations of propranolol are increased in combination with fluvoxamine, the propranolol dose may need to be lowered.</p><p>&nbsp;</p><p>When given with fluvoxamine, warfarin plasma concentrations were significantly increased and prothrombin times prolonged.</p><p>&nbsp;</p><p><em><u>Cases of increased side effects</u></em></p><p>Isolated cases of cardiac toxicity have been reported when fluvoxamine was combined with thioridazine.</p><p>&nbsp;</p><p>Caffeine plasma levels are likely to be increased during co-administration with fluvoxamine. Thus, patients who consume high quantities of caffeine-containing beverages should lower their intake when fluvoxamine is administered and adverse caffeine effects (like tremor, palpitations, nausea, restlessness, insomnia) are observed.</p><p>&nbsp;</p><p>Terfenadine, astemizole, cisapride , sildenafil (see also section 4.4). Fluvoxamine does not influence plasma concentrations of digoxin.</p><p>Fluvoxamine does not influence plasma concentrations of atenolol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Epidemiological data have suggested that the use of Selective Serotonin Reuptake Inhibitors (SSRIs) in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). The observed risk was approximately 5 cases per 1000 pregnancies. In the general population 1 to 2 cases of PPHN per 1000 pregnancies occur.</p><p>&nbsp;</p><p>Reproduction toxicity studies in animals revealed treatment related increases in embryotoxicity (embryofetal death, fetal eye abnormalities).. The relevance to humans is unknown. The safety margin for reproductive toxicity is unknown (see section 5.3).</p><p>&nbsp;</p><p>Faverin should not be used during pregnancy unless the clinical condition of the woman requires treatment with fluvoxamine.</p><p>&nbsp;</p><p>Observational data indicate an increased risk (less than 2-fold) of postpartum haemorrhage following SSRI exposure within the month prior to birth (see sections 4.4, 4.8).</p><p>&nbsp;</p><p>Isolated cases of withdrawal symptoms in the newborn child have been described after the use of fluvoxamine at the end of pregnancy.</p><p>&nbsp;</p><p>Some newborns experience feeding and/or respiratory difficulties, seizures, temperature instability, hypoglycaemia, tremor, abnormal muscle tone, jitteriness, cyanosis, irritability, lethargy, somnolence, vomiting, difficulty in sleeping and constant crying after third trimester exposure to SSRIs and may require prolonged hospitalization.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>Fluvoxamine is excreted via human milk in small quantities. Therefore, the drug should not be used by women who breast feed. There are no data on the effect of fluvoxamine in milk production.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Reproductive toxicity studies in animals have shown that Faverin impairs male and female fertility. The safety margin for this effect was not identified. The relevance of these findings to humans is unknown (see section 5.3).</p><p>&nbsp;</p><p>Animal data have shown that fluvoxamine may affect sperm quality (see section 5.3). Human case reports with some SSRIs have shown that an effect on sperm quality is reversible. Impact on human fertility has not been observed so far.</p><p>&nbsp;</p><p>Faverin should not be used in patients attempting to conceive unless the clinical condition of the patient requires treatment with fluvoxamine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fluvoxamine up to 150 mg has no or negligible influence on the ability to drive and use machines. It showed no effect on psychomotor skills associated with driving and operating machinery in healthy volunteers. However, somnolence has been reported during treatment with fluvoxamine. Therefore, caution is recommended until the individual response to the drug has been determined.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse effects, observed in clinical studies at frequencies listed below, are often<br />associated with the illness and are not necessarily related to the treatment with<br />fluvoxamine.<br />Frequency estimate: very common ( 1/10), common ( 1/100, 1/10), uncommon ( 1/1.000,<br />1/100), rare ( 1/10.000 to 1/1.000), very rare (&lt;1/10.000), not known (cannot be estimated<br />from the available data).</p><table border="1" cellspacing="1" cellpadding="1" style="width:827px"><tbody><tr><td style="width:141px">System/organclass<br />according to<br />MedDRA</td><td style="width:124px">Common</td><td style="width:122px">Uncommon</td><td style="width:141px">Rare</td><td style="width:158px">Very rare</td><td style="width:144px">Frequency not<br />known</td></tr><tr><td style="width:141px">Endocrine<br />disorders</td><td style="width:124px">&nbsp;</td><td style="width:122px">&nbsp;</td><td style="width:141px">&nbsp;</td><td style="width:158px">&nbsp;</td><td style="width:144px">Hyperprolactinemia,<br />Inadequate<br />antidiuretic<br />hormone<br />secretion</td></tr><tr><td style="width:141px">Metabolism and<br />nutrition<br />disorders</td><td style="width:124px">Anorexia</td><td style="width:122px">&nbsp;</td><td style="width:141px">&nbsp;</td><td style="width:158px">&nbsp;</td><td style="width:144px">Hyponatreamia,<br />weight increase,<br />weight decrease</td></tr><tr><td style="width:141px">Psychiatric<br />disorders</td><td style="width:124px">&nbsp;</td><td style="width:122px">Hallucination,<br />Confusion</td><td style="width:141px">Mania</td><td style="width:158px">&nbsp;</td><td style="width:144px">Suicidal<br />ideation and<br />suicidal<br />behaviour (see<br />section 4.4)</td></tr><tr><td style="width:141px">Nervous system<br />disorders</td><td style="width:124px">Agitation,<br />Nervousness,<br />Anxiety,<br />Insomnia,<br />Drowsiness,<br />Tremor,<br />Headache,<br />Dizziness</td><td style="width:122px">Extrapyramidal<br />disorder, Ataxia</td><td style="width:141px">Convulsion</td><td style="width:158px">&nbsp;</td><td style="width:144px">Serotonin syndrome,<br />Neuroleptic<br />malignant<br />syndrome like<br />events<br />, Paresthesia,<br />Dysgeusia and<br />SIADH have<br />been reported<br />(see also section<br />4.4). Psychomotor<br />restlessness/<br />akathisia (see<br />section 4.4)</td></tr><tr><td style="width:141px">Eye disorders</td><td style="width:124px">&nbsp;</td><td style="width:122px">&nbsp;</td><td style="width:141px">&nbsp;</td><td style="width:158px">&nbsp;</td><td style="width:144px">Glaucoma.<br />Mydriasis</td></tr><tr><td style="width:141px">Renal and urinary<br />disorders</td><td style="width:124px">&nbsp;</td><td style="width:122px">&nbsp;</td><td style="width:141px">&nbsp;</td><td style="width:158px">&nbsp;</td><td style="width:144px">Micturition<br />disorder<br />(including<br />urine retention,<br />-incontinence,<br />pollakiuria,<br />nocturia and<br />enuresis)</td></tr><tr><td style="width:141px">Cardiac disorders</td><td style="width:124px">Palpitations/<br />tachycardia</td><td style="width:122px">&nbsp;</td><td style="width:141px">&nbsp;</td><td style="width:158px">&nbsp;</td><td style="width:144px">&nbsp;</td></tr><tr><td style="width:141px">Vascular disorders</td><td style="width:124px">&nbsp;</td><td style="width:122px">(Orthostatic)<br />hypotension</td><td style="width:141px">&nbsp;</td><td style="width:158px">&nbsp;</td><td style="width:144px"><p>Haemorrhage<br />(e.g.<br />gastrointestinal<br />haemorrhage,<br />gynaecological<br />haemorrhage,<br />ecchymosis,<br />purpura)</p><p>postpartum</p><p>haemorrhage****</p></td></tr><tr><td style="width:141px">Gastrointestinal<br />disorders</td><td style="width:124px">Abdominal<br />pain,<br />Constipation,<br />Diarrrhoea,<br />Dry mouth,<br />Dyspepsia,<br />Nausea,<br />Vomiting</td><td style="width:122px">&nbsp;</td><td style="width:141px">&nbsp;</td><td style="width:158px">&nbsp;</td><td style="width:144px">&nbsp;</td></tr><tr><td style="width:141px">Hepatobiliary<br />disorders</td><td style="width:124px">&nbsp;</td><td style="width:122px">&nbsp;</td><td style="width:141px">Abnormal<br />hepatic<br />function</td><td style="width:158px">&nbsp;</td><td style="width:144px">&nbsp;</td></tr><tr><td style="width:141px">Skin and<br />subcutaneous tissue<br />disorders</td><td style="width:124px">Hyperhidrosis,<br />Sweating</td><td style="width:122px">Cutaneous<br />hypersensitivity<br />(incl.<br />angioneurotic<br />oedema, rash,<br />pruritus)</td><td style="width:141px">Photosensitivity<br />reaction</td><td style="width:158px">&nbsp;</td><td style="width:144px"><p>Stevens- Johnson syndrome***/</p><p>Toxic Epidermal Necrolysis***,</p>Erythema multiforme***</td></tr><tr><td style="width:141px">Musculoskeletal<br />connective tissue<br />and bone disorders</td><td style="width:124px">&nbsp;</td><td style="width:122px">Arthralgia,<br />Myalgia</td><td style="width:141px">&nbsp;</td><td style="width:158px">&nbsp;</td><td style="width:144px">** Bone<br />fractures</td></tr><tr><td style="width:141px">Reproductive<br />system and breast<br />disorders</td><td style="width:124px">&nbsp;</td><td style="width:122px">Abnormal<br />(delayed<br />ejaculation)</td><td style="width:141px">Galactorrhea</td><td style="width:158px">&nbsp;</td><td style="width:144px">Anorgasmia,<br />Menstrual<br />disorders (such<br />as amenorrhea,<br />hypomenorrhea<br />, metrorrhagia,<br />menorrhagia)</td></tr><tr><td style="width:141px">General disorders<br />and administration<br />site reactions</td><td style="width:124px">Asthenia,<br />malaise</td><td style="width:122px">&nbsp;</td><td style="width:141px">&nbsp;</td><td style="width:158px">&nbsp;</td><td style="width:144px">Drug<br />withdrawal<br />syndrome<br />including Drug<br />withdrawal<br />syndrome<br />neonatal (see<br />section 4.6)</td></tr></tbody></table><p>*Nausea, sometimes accompanied by vomiting is the most frequently observed symptom associated with fluvoxamine treatment. This side effect usually diminishes within the first two weeks of treatment.</p><p>**Class effects: Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving Selective Serotonin Reuptake Inhibitors (SSRIs) and Tricyclic Antidepressants (TCAs). The mechanism leading to this risk is unknown.</p><p>***Estimated frequency of post-marketing surveillance reported adverse reactions; not observed in placebo- controlled clinical trials</p><p>**** This event has been reported for the therapeutic class of SSRIs (see sections 4.4, 4.6).</p><p>&nbsp;</p><p>&nbsp;</p><p>Cases of suicidal ideation and suicidal behaviours have been reported during fluvoxamine therapy or early after treatment discontinuation (see section 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p><strong><em>Withdrawal symptoms seen on discontinuation of fluvoxamine treatment </em></strong>Discontinuation of fluvoxamine (particularly when abrupt) commonly leads to withdrawal symptoms. Dizziness, sensory disturbance (including paraesthesia, visual disturbance and electric shock sensations), sleep disturbances (including insomnia and intense dreams), agitation and anxiety, irritability, confusion, emotional instability, nausea and/or vomiting, diarrhoea, sweating, palpitations, headache and tremor are the most commonly reported reactions. Generally these events are mild to moderate and are self-limiting; however, in some patients they may be severe and/or prolonged. It is therefore advised that when fluvoxamine treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see section</p><p>4.2 and section 4.4).</p><p>&nbsp;</p><p><strong><em>Paediatric population</em></strong></p><p>In one 10-week placebo-controlled trial in children and adolescents with OCD, frequently reported adverse events with a higher incidence than placebo, were: insomnia, asthenia, agitation, hyperkinesia, somnolence and dyspepsia. Serious adverse events in this study included: agitation and hypomania.</p><p>&nbsp;</p><p>Convulsions in children and adolescents have been reported during use outside clinical trials.</p><p>&nbsp;</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p><strong>To report any side effect(s):</strong></p><p>-National Pharmacovigilance Center (NPC)</p><p><strong>o </strong>Fax: +966-11-205-7662</p><p><strong>o </strong>SFDA Call Center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Symptoms</em></p><p>Symptoms include gastro-intestinal complaints (nausea, vomiting and diarrhoea), somnolence and dizziness. Cardiac events (tachycardia, bradycardia, hypotension), liver function disturbances, convulsions and coma have also been reported.</p><p>&nbsp;</p><p>Fluvoxamine has a wide margin of safety in overdose. Since market introduction, reports of deaths attributed to overdose of fluvoxamine alone have been extremely rare. The highest documented dose of fluvoxamine ingested by a patient is 12 grams. This patient recovered completely. Occasionally, more serious complications were observed in cases of deliberate overdose of fluvoxamine in combination with other drugs.</p><p>&nbsp;</p><p><em>Treatment</em></p><p>There is no specific antidote to fluvoxamine. In case of overdose the stomach should be emptied as soon as possible after tablet ingestion and symptomatic treatment should be given. The repeated use of medicinal charcoal, if necessary accompanied by an osmotic laxative, is also recommended. Forced diuresis or dialysis is unlikely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antidepressants, Selective serotonin reuptake inhibitors, ATC code: N06AB08.</p><p>&nbsp;</p><p>The mechanism of action of fluvoxamine is thought to be related to selective serotonin re-uptake inhibition in brain neurones. There is minimum interference with noradrenergic processes. Receptor binding studies have demonstrated that fluvoxamine has negligible binding capacity to alpha adrenergic, beta adrenergic, histaminergic, muscarine cholinergic, dopaminergic or serotonergic receptors.</p><p>&nbsp;</p><p>In a placebo controlled trial in 120 patients with OCD, aged between 8 and 17 years, a statistically significant improvement was seen in the total population in favour of fluvoxamine at 10 weeks. A further subgroup analysis showed improvement on the C- YBOCS rating scale in children whereas no effect was seen in adolescents. The mean dose was respectively 158 mg and 168 mg/day.</p><p>&nbsp;</p><p><em>Dose response</em></p><p>&nbsp;</p><p>No formal clinical trials were conducted investigating the dose response of fluvoxamine. However, it is clinical experience that up-titrating the dose might be beneficial for some patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Absorption</em></p><p>Fluvoxamine is completely absorbed following oral administration. Maximum plasma concentrations occur within 3-8 hours of dosing. The mean absolute bioavailability is 53% due to first-pass metabolism.</p><p>The pharmacokinetics of fluvoxamine is not influenced by concomitant food intake.</p><p>&nbsp;</p><p><em>Distribution</em></p><p><em>In vitro </em>plasma protein binding of fluvoxamine is 80%. Volume of distribution in humans is 25 l/kg.</p><p>&nbsp;</p><p><em>Metabolism</em></p><p>Fluvoxamine undergoes extensive metabolism in the liver. Although CYP2D6 is <em>in vitro </em>the main isoenzyme involved in fluvoxamine&rsquo;s metabolism, plasma concentrations in poor metabolisers for CYP2D6 are not much higher than those in extensive metabolisers.</p><p>&nbsp;</p><p>The mean plasma half-life is approximately 13-15 hours after a single dose and slightly longer (17-22 hours) during repeated dosing, when steady-state plasma levels are usually achieved within 10-14 days.</p><p>&nbsp;</p><p>Fluvoxamine undergoes extensive hepatic transformation, mainly via oxidative demethylation, into at least nine metabolites, which are excreted by the kidneys. The two major metabolites showed negligible pharmacological activity. The other metabolites are not expected to be pharmacologically active. Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C19. A moderate inhibition was found for CYP2C9, CYP2D6 and CYP3A4.</p><p>&nbsp;</p><p>Fluvoxamine displays linear single-dose pharmacokinetics. Steady-state concentrations are higher than calculated from single-dose data, and this disproportional increase is more pronounced with higher daily doses.</p><p>&nbsp;</p><p><em>Special Patients groups</em></p><p>The pharmacokinetics of fluvoxamine is similar in healthy adults, elderly patients, and patients with renal insufficiency. The metabolism of fluvoxamine is impaired in patients with liver disease.</p><p>&nbsp;</p><p>Steady-state plasma concentrations of fluvoxamine were twice as high in children (aged 6-11) as in adolescents (aged 12-17). Plasma concentrations in adolescents are similar to those in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Carcinogenesis and mutagenesis</em></p><p>There is no evidence of carcinogenicity or mutagenicity with fluvoxamine.</p><p>&nbsp;</p><p><em>Fertility and reproductive toxicity</em></p><p>Animal studies on male and female fertility revealed reduction of mating performance, decreased sperm count and fertility index and increased ovary weights at levels higher than human exposure. The effects were observed at exposures &gt; two- fold higher than exposure at the maximum therapeutic dose. As there is no safety margin between exposure at the NOAEL in the reproductive studies and the exposure at the maximum therapeutic dose a risk to patients cannot be ruled out.</p><p>&nbsp;</p><p>Reproductive toxicity studies in rats have shown that fluvoxamine is embryotoxic (increased embryofetal death [resorptions], increased fetal eye abnormalities [folded retina], reduced fetal weights and delayed ossification). The effects on fetal weights and ossification are likely to be secondary to maternal toxicity (reduced maternal bodyweight and bodyweight gain).</p><p>&nbsp;</p><p>In addition an increased incidence of perinatal pup mortality in pre-and postnatal studies was seen.</p><p>&nbsp;</p><p>The safety margin for reproductive toxicity is unknown.</p><p>&nbsp;</p><p><em>Physical and psychological dependence</em></p><p>The potential for abuse, tolerance and physical dependence has been studied in a non- human primate model. No evidence of dependency phenomena was found.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablet cores:</em></p><p>Mannitol</p><p>Maize starch</p><p>Pregelatinised starch</p><p>Sodium stearyl fumarate</p><p>Colloidal anhydrous silica</p><p>&nbsp;</p><p><em>Film-coat:</em></p><p>Hypromellose</p><p>Macrogol 6000</p><p>Talc</p><p>Titanium Dioxide E171</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC / PVDC / Aluminium blister packs<br />Fevarin 50 mg tablets are available in boxes of 5, 10, 20, 30, 50, 60 90, 100 and 250 tablets.<br />Fevarin 100 mg tablets are available in boxes of 15, 20, 30,50, 60, 90, 100, 120 or 250 tablets.<br />Not all the pack sizes mentioned are marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Abbott Healthcare products B.V
The Netherlands
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2021 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>